Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV000658632 | SCV000780414 | uncertain significance | not provided | 2017-12-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001376777 | SCV001573941 | likely pathogenic | TNF receptor-associated periodic fever syndrome (TRAPS) | 2022-07-26 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with histidine, which is basic and polar, at codon 41 of the TNFRSF1A protein (p.Asp41His). This variant is present in population databases (rs199882512, gnomAD 0.002%). This variant has not been reported in the literature in individuals affected with TNFRSF1A-related conditions. ClinVar contains an entry for this variant (Variation ID: 546694). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt TNFRSF1A protein function. This variant disrupts the p.Asp41 amino acid residue in TNFRSF1A. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 23322460). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |